Evidence map›Paper›PMID 30397836›Full record

ArticleInvestigational new drugs2019

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [

Xiaofei Zhou, Sandeepraj Pusalkar, Swapan K Chowdhury, Shawn Searle, Yuexian Li, Claudio Dansky Ullmann, Karthik Venkatakrishnan

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Biotransformation Pathways and Metabolite Profiles of Oral [Drug metabolism and disposition: the biological fate of chemicals · 2020
    Article
  4. The role of Aurora-A in human cancers and future therapeutics.American journal of cancer research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Xiaofei ZhouQuantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. xiaofei.zhou@takeda.com.ORCID 0000-0003-0319-1327
Sandeepraj PusalkarQuantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Swapan K ChowdhuryQuantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Shawn SearlePRA Health Sciences, Salt Lake City, UT, USA.
Yuexian LiQuantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Claudio Dansky UllmannMaxCyte, Inc., Gaithersburg, MD, USA.
Karthik VenkatakrishnanQuantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Takeda (United States) · USMaxCyte (United States) · USPRA Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics and safety of the investigational aurora A kinase inhibitor, alisertib, in three patients with advanced malignancies. Methods Part A; patients received a single 35-mg dose of [

Indexed as

Administration, OralAgedAntineoplastic AgentsAurora Kinase AAzepinesFecesFemaleHumansMaleMiddle AgedNeoplasmsProtein Kinase InhibitorsPyrimidinesAntineoplastic AgentsAURKA protein, humanAurora Kinase AAzepinesMLN 8237Protein Kinase InhibitorsPyrimidinesAlisertibAurora A kinaseMass balancePharmacokinetics

Identifiers

PMID30397836
OpenAlexW2899524963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.